Enrico Cortesi Selected Research

Breast Neoplasms (Breast Cancer)

5/2022	Immune effects of CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: Relief from immunosuppression is associated with clinical response.
1/2021	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET).
1/2021	The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial.
1/2021	PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting.
12/2020	Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study.
11/2020	Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence.
1/2020	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
1/2019	Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.
1/2014	Clinical utility of circulating tumor cell counting through CellSearch(®): the dilemma of a concept suspended in Limbo.
10/2013	Treatment of peritoneal carcinomatosis from breast cancer by maximal cytoreduction and HIPEC: a preliminary report on 5 cases.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Enrico Cortesi Research Topics

Disease

42	Neoplasms (Cancer) 05/2022 - 09/2003
25	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/2022 - 12/2002
24	Colorectal Neoplasms (Colorectal Cancer) 02/2022 - 03/2003
23	Breast Neoplasms (Breast Cancer) 05/2022 - 03/2003
19	Renal Cell Carcinoma (Grawitz Tumor) 10/2020 - 07/2010
14	Neoplasm Metastasis (Metastasis) 02/2022 - 03/2003
11	Prostatic Neoplasms (Prostate Cancer) 06/2021 - 03/2012
9	Circulating Neoplastic Cells 01/2017 - 05/2010
6	Rectal Neoplasms (Rectal Cancer) 02/2022 - 07/2010
5	Brain Neoplasms (Brain Tumor) 04/2020 - 05/2018
5	Anemia 01/2010 - 01/2004
4	Lung Neoplasms (Lung Cancer) 06/2022 - 10/2004
4	Colonic Neoplasms (Colon Cancer) 01/2021 - 09/2019
4	Disease Progression 11/2019 - 07/2011
4	Pain (Aches) 09/2019 - 07/2006
4	Fatigue 01/2019 - 01/2005
3	Urinary Bladder Neoplasms (Bladder Cancer) 01/2022 - 09/2010
3	Carcinoma (Carcinomatosis) 04/2020 - 10/2003
3	Hypothyroidism 01/2020 - 07/2011
3	Hypertension (High Blood Pressure) 01/2019 - 09/2010
3	Diarrhea 11/2018 - 03/2008
3	Adenocarcinoma 09/2018 - 03/2008
3	Neutropenia 03/2012 - 03/2003
3	Stomach Neoplasms (Stomach Cancer) 08/2010 - 04/2007
2	Inflammation (Inflammations) 12/2021 - 01/2020
2	Melanoma (Melanoma, Malignant) 04/2020 - 01/2020
2	Lymphatic Metastasis 09/2017 - 04/2007
2	Stomatitis 01/2013 - 09/2010
2	Exanthema (Rash) 03/2012 - 07/2008
2	Cardiotoxicity 12/2011 - 11/2002
2	Vomiting 08/2011 - 03/2008
2	Febrile Neutropenia 09/2010 - 10/2005
2	Osteolysis 01/2008 - 01/2007

Drug/Important Bio-Agent (IBA)

12	NivolumabIBA 06/2022 - 01/2016
11	Cisplatin (Platino)FDA LinkGeneric 10/2013 - 03/2003
10	Fluorouracil (Carac)FDA LinkGeneric 10/2014 - 03/2003
9	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2016
9	Oxaliplatin (Eloxatin)FDA LinkGeneric 09/2019 - 03/2003
8	Docetaxel (Taxotere)FDA Link 11/2019 - 11/2002
8	Irinotecan (Camptosar)FDA LinkGeneric 09/2018 - 05/2007
7	Biomarkers (Surrogate Marker)IBA 11/2020 - 01/2014
7	Tyrosine Kinase InhibitorsIBA 10/2015 - 07/2011
6	Bevacizumab (Avastin)FDA Link 02/2022 - 09/2010
6	Everolimus FDA Link 01/2021 - 07/2011
6	Leucovorin (Folinic Acid)FDA Link 09/2018 - 04/2007
6	Paclitaxel (Taxol)FDA LinkGeneric 03/2007 - 12/2002
5	Biological ProductsIBA 01/2017 - 05/2010
4	pertuzumabIBA 01/2021 - 01/2020
4	Circulating Tumor DNAIBA 01/2021 - 01/2015
4	cabozantinibIBA 10/2020 - 01/2018
4	Abiraterone AcetateIBA 10/2020 - 03/2012
4	ErbB Receptors (EGF Receptor)IBA 01/2019 - 08/2007
4	Sunitinib (Sutent)FDA Link 01/2019 - 07/2011
4	Epoetin Alfa (Epogen)FDA Link 01/2010 - 01/2004
4	Epirubicin (Ellence)FDA LinkGeneric 03/2008 - 09/2003
4	Gemcitabine FDA Link 12/2003 - 03/2003
3	Radium-223IBA 06/2021 - 11/2018
3	B7-H1 AntigenIBA 04/2020 - 01/2016
3	PlatinumIBA 11/2019 - 10/2004
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 06/2014 - 03/2011
3	Sorafenib (BAY 43-9006)FDA Link 02/2013 - 07/2011
3	AnthracyclinesIBA 12/2011 - 03/2003
3	Hemoglobins (Hemoglobin)IBA 01/2010 - 01/2005
3	Filgrastim (Neupogen)FDA Link 04/2007 - 10/2005
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 07/2006 - 09/2003
3	lonidamineIBA 07/2006 - 09/2003
3	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 07/2006 - 09/2003
2	Cell-Free Nucleic AcidsIBA 11/2021 - 12/2020
2	RadiumIBA 03/2021 - 10/2020
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 10/2005
2	Hormones (Hormone)IBA 01/2021 - 01/2019
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2021 - 01/2019
2	Ado-Trastuzumab EmtansineIBA 01/2021 - 11/2020
2	exemestane (Aromasin)FDA Link 01/2021 - 01/2019
2	DNA (Deoxyribonucleic Acid)IBA 12/2020 - 01/2015
2	Yttrium-90IBA 12/2020 - 11/2009
2	Transaminases (Aminotransferases)IBA 01/2019 - 11/2018
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 10/2014
2	Proteins (Proteins, Gene)FDA Link 01/2015 - 11/2004
2	Monoclonal AntibodiesIBA 10/2014 - 08/2007
2	Panitumumab (Vectibix)FDA Link 07/2014 - 08/2007
2	InterferonsIBA 02/2013 - 07/2011
2	Estrogens (Estrogen)FDA Link 01/2013 - 09/2011
2	Keratins (Keratin)IBA 12/2011 - 05/2011
2	SurvivinIBA 09/2010 - 08/2010
2	Zoledronic Acid (Zometa)FDA Link 01/2008 - 01/2007
2	Pamidronate (Aredia)FDA LinkGeneric 01/2008 - 01/2007
2	AntigensIBA 01/2006 - 11/2004

Therapy/Procedure

37	Therapeutics 05/2022 - 01/2004
35	Drug Therapy (Chemotherapy) 12/2020 - 03/2003
10	Radiotherapy 06/2022 - 10/2004
10	Castration 06/2021 - 03/2012
9	Immunotherapy 06/2022 - 10/2014
7	Neoadjuvant Therapy 02/2022 - 07/2010
7	Adjuvant Chemotherapy 05/2021 - 11/2002
5	Induction Chemotherapy 12/2020 - 10/2003
2	Chemoradiotherapy 02/2022 - 01/2019
2	Consolidation Chemotherapy 01/2019 - 03/2007
2	Palliative Care (Palliative Therapy) 03/2011 - 01/2007
1	Immunomodulation 05/2022